Management of Non Convulsive Status Epilepticus

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03245099

Enrollment

100

Registered

2017-08-10

Start date

2017-12-31

Completion date

2019-04-30

Last updated

2017-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Status Epilepticus

Brief summary

Non convulsive status epilepticus is a persistent change in behavioural and or mental process from baseline associated with continuous epileptiform activity in electroencephalograph,it occur in about 50 percent in patients with coma and convulsions and in 8-13 percent in intensive care unit patients

Detailed description

Early recognition and treatment of non convulsive status epilepticus are essential to optimize response to treatment and to prevent neurological sequelae, over diagnosis and aggressive use of anticonvulsants can contribute to morbidity and mortality.It displays great diversity in response to anticonvulsants,therefore treatment in intensive care units is required for selected cases .The aetiology and clinical forms are strong predictors for the overall prognosis.Treatment is poorly understood and follows the standard regimen for convulsive status epilepticus

Interventions

OTHERcross sectional

Electroencephalograph will be done to all patients who fulfill the inclusion criteria to detect presence of electrical discharge with in the brain.Complete blood count ,liver function test ,kidney function test ,blood glucose level and serum electrolytes will be done to selected cases according to the clinical presentation

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

12 Months to 18 Years

Healthy volunteers

Inclusion criteria

* patients who have generalized tonic colonic convulsions and prolonged post ictal state more than 30 minutes * patients presented with un explained psychic or speech disorder * patients presented with stupor or confusion * Patients presented with un explained coma

Exclusion criteria

* patients with progressive neurological disease * Patients with severe cerebral anoxia * Patients with liver or hepatic impairment

Design outcomes

Primary

Measure	Time frame	Description
Number of cured patients	An average of 1 year	Number of cured patients

Countries

Egypt

Contacts

Primary ContactGamal Askar, MD

Gamal.askar@med.au.edu.eg01111686162

Backup ContactEman Fathallah, MD

Mean.mohamed@med.au.edu.eg01115191158

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026